| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Aflibercept |
| Brand | Eylea® |
| Indication | For the treatment of neovascular (wet) age-related macular degeneration (AMD). |
| Assessment Process | |
| Rapid review commissioned | 10/12/2012 |
| Rapid review completed | 21/12/2012 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended |